Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001839461 | SCV001441465 | uncertain significance | Intellectual disability, autosomal dominant 5 | 2020-06-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001839461 | SCV002273662 | benign | Intellectual disability, autosomal dominant 5 | 2024-08-08 | criteria provided, single submitter | clinical testing | |
Ce |
RCV002275337 | SCV002563890 | uncertain significance | not provided | 2022-07-01 | criteria provided, single submitter | clinical testing | SYNGAP1: PP2 |
Ambry Genetics | RCV004035414 | SCV004961440 | uncertain significance | Inborn genetic diseases | 2023-09-26 | criteria provided, single submitter | clinical testing | The c.1904A>G (p.N635S) alteration is located in exon 11 (coding exon 11) of the SYNGAP1 gene. This alteration results from a A to G substitution at nucleotide position 1904, causing the asparagine (N) at amino acid position 635 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |